Skip to main content
Premium Trial:

Request an Annual Quote

Amgen, NeoGenomics Partner to Expand Biomarker Testing Access in NSCLC

NEW YORK — Amgen said on Monday that it has partnered with NeoGenomics as part of a new program to expand biomarker testing access to all advanced or metastatic non-small cell lung cancer patients.

The new program, dubbed Biomarker Assist, consists of two efforts. Through the first part, the Next-Generation Sequencing Affordability Program, Amgen will provide financial assistance to advanced NSCLC patients facing out-of-pocket costs for comprehensive biomarker panels. To be eligible, patients must have commercial or private insurance and the NGS panel must include the KRAS gene.

Through the program's second part, the KRAS Single Gene Test Program, Thousand Oaks, California-based Amgen will cover the cost of Fort Myers, Florida-based NeoGenomics' single-gene tests for the KRAS G12C driver mutation for all patients with advanced or metastatic NSCLC regardless of their insurance status or results. Both programs will remain valid for testing performed through the end of the year.

"Unfortunately, many patients still do not receive biomarker testing due to barriers in education, access, and reimbursement," Darryl Sleep, Amgen's chief medical officer and senior VP of global medicine, said in a statement. "Amgen's Biomarker Assist program is designed to help more patients with advanced non-small cell lung cancer gain access to testing. NeoGenomics' KRAS Single Gene Test is an important component of this program."

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.